vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and ZIPRECRUITER, INC. (ZIP). Click either name above to swap in a different company.
ZIPRECRUITER, INC. is the larger business by last-quarter revenue ($111.7M vs $57.3M, roughly 2.0× RHYTHM PHARMACEUTICALS, INC.). ZIPRECRUITER, INC. runs the higher net margin — -0.7% vs -83.0%, a 82.2% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 0.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -4.4%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ZipRecruiter, Inc. is an American employment marketplace for job seekers and employers.
RYTM vs ZIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $111.7M |
| Net Profit | $-47.5M | $-835.0K |
| Gross Margin | 91.6% | 89.1% |
| Operating Margin | -82.2% | 3.6% |
| Net Margin | -83.0% | -0.7% |
| Revenue YoY | 36.9% | 0.6% |
| Net Profit YoY | -9.6% | 92.3% |
| EPS (diluted) | $-0.73 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $111.7M | ||
| Q3 25 | $51.3M | $115.0M | ||
| Q2 25 | $48.5M | $112.2M | ||
| Q1 25 | $32.7M | $110.1M | ||
| Q4 24 | $41.8M | $111.0M | ||
| Q3 24 | $33.3M | $117.1M | ||
| Q2 24 | $29.1M | $123.7M | ||
| Q1 24 | $26.0M | $122.2M |
| Q4 25 | $-47.5M | $-835.0K | ||
| Q3 25 | $-52.9M | $-9.8M | ||
| Q2 25 | $-46.6M | $-9.5M | ||
| Q1 25 | $-49.5M | $-12.8M | ||
| Q4 24 | $-43.3M | $-10.8M | ||
| Q3 24 | $-43.6M | $-2.6M | ||
| Q2 24 | $-32.3M | $7.0M | ||
| Q1 24 | $-141.4M | $-6.5M |
| Q4 25 | 91.6% | 89.1% | ||
| Q3 25 | 89.3% | 89.1% | ||
| Q2 25 | 88.6% | 89.3% | ||
| Q1 25 | 88.8% | 89.4% | ||
| Q4 24 | 90.9% | 89.6% | ||
| Q3 24 | 88.5% | 89.4% | ||
| Q2 24 | 89.9% | 89.5% | ||
| Q1 24 | 89.2% | 89.1% |
| Q4 25 | -82.2% | 3.6% | ||
| Q3 25 | -102.6% | -4.4% | ||
| Q2 25 | -93.4% | -5.9% | ||
| Q1 25 | -143.7% | -10.6% | ||
| Q4 24 | -98.6% | -3.6% | ||
| Q3 24 | -132.0% | -2.8% | ||
| Q2 24 | -139.2% | 7.6% | ||
| Q1 24 | -538.7% | -0.7% |
| Q4 25 | -83.0% | -0.7% | ||
| Q3 25 | -103.1% | -8.5% | ||
| Q2 25 | -96.1% | -8.5% | ||
| Q1 25 | -151.4% | -11.7% | ||
| Q4 24 | -103.6% | -9.7% | ||
| Q3 24 | -131.2% | -2.2% | ||
| Q2 24 | -110.9% | 5.7% | ||
| Q1 24 | -544.4% | -5.3% |
| Q4 25 | $-0.73 | $-0.03 | ||
| Q3 25 | $-0.82 | $-0.11 | ||
| Q2 25 | $-0.75 | $-0.10 | ||
| Q1 25 | $-0.81 | $-0.13 | ||
| Q4 24 | $-0.71 | $-0.10 | ||
| Q3 24 | $-0.73 | $-0.03 | ||
| Q2 24 | $-0.55 | $0.07 | ||
| Q1 24 | $-2.35 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $188.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $-77.2M |
| Total Assets | $480.2M | $569.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $188.0M | ||
| Q3 25 | $416.1M | $211.8M | ||
| Q2 25 | $291.0M | $203.5M | ||
| Q1 25 | $314.5M | $221.1M | ||
| Q4 24 | $320.6M | $218.4M | ||
| Q3 24 | $298.4M | $225.6M | ||
| Q2 24 | $319.1M | $271.7M | ||
| Q1 24 | $201.2M | $282.5M |
| Q4 25 | $139.1M | $-77.2M | ||
| Q3 25 | $148.8M | $-76.1M | ||
| Q2 25 | $-11.9M | $-65.9M | ||
| Q1 25 | $18.9M | $-11.3M | ||
| Q4 24 | $21.7M | $13.4M | ||
| Q3 24 | $11.2M | $13.6M | ||
| Q2 24 | $39.3M | $24.4M | ||
| Q1 24 | $61.6M | $12.7M |
| Q4 25 | $480.2M | $569.7M | ||
| Q3 25 | $506.9M | $573.6M | ||
| Q2 25 | $372.7M | $592.4M | ||
| Q1 25 | $386.7M | $629.4M | ||
| Q4 24 | $392.3M | $664.1M | ||
| Q3 24 | $363.6M | $652.0M | ||
| Q2 24 | $381.8M | $665.3M | ||
| Q1 24 | $258.7M | $662.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $7.7M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.8% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $7.7M | ||
| Q3 25 | $-26.6M | $2.6M | ||
| Q2 25 | $-23.3M | $10.5M | ||
| Q1 25 | $-40.4M | $-9.9M | ||
| Q4 24 | $-18.8M | $12.5M | ||
| Q3 24 | $-25.2M | $9.3M | ||
| Q2 24 | $-29.1M | $21.9M | ||
| Q1 24 | $-40.7M | $2.0M |
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $-10.2M | ||
| Q4 24 | — | $12.0M | ||
| Q3 24 | — | $9.2M | ||
| Q2 24 | — | $21.7M | ||
| Q1 24 | — | $1.9M |
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 9.1% | ||
| Q1 25 | — | -9.3% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
ZIP
| License | $84.3M | 75% |
| Services | $27.4M | 25% |
